Zobrazeno 1 - 7
of 7
pro vyhledávání: '"Triulzi, Tiziana"'
Autor:
Pizzamiglio S; Bioinformatics and Biostatistics Unit, Department of Applied Research and Technological Development, Fondazione IRCCS Istituto Nazionale dei Tumori, Milan, Italy., Cosentino G; Molecular Targeting Unit, Department of Research, Fondazione IRCCS Istituto Nazionale dei Tumori, Milan, Italy., Ciniselli CM; Bioinformatics and Biostatistics Unit, Department of Applied Research and Technological Development, Fondazione IRCCS Istituto Nazionale dei Tumori, Milan, Italy., De Cecco L; Integrated Biology Platform, Department of Applied Research and Technological Development, Fondazione IRCCS Istituto Nazionale dei Tumori, Milan, Italy., Cataldo A; Molecular Targeting Unit, Department of Research, Fondazione IRCCS Istituto Nazionale dei Tumori, Milan, Italy., Plantamura I; Molecular Targeting Unit, Department of Research, Fondazione IRCCS Istituto Nazionale dei Tumori, Milan, Italy., Triulzi T; Molecular Targeting Unit, Department of Research, Fondazione IRCCS Istituto Nazionale dei Tumori, Milan, Italy., El-Abed S; Breast International Group (BIG), Brussels, Belgium., Wang Y; Novartis Pharma AG, Basel, Switzerland., Bajji M; Institute Jules Bordet (IJB), Brussels, Belgium., Nuciforo P; Molecular Oncology Group, Vall d'Hebron Institute of Oncology (VHIO), Barcelona, Spain., Huober J; Breast Center, Cantonal Hospital, St. Gallen, Switzerland., Ellard SL; BC Cancer, Kelowna, British Columbia, Canada., Rimm DL; Department of Pathology, Yale University School of Medicine, New Haven, Connecticut, USA., Gombos A; Institute Jules Bordet (IJB), Brussels, Belgium., Daidone MG; Biomarkers Unit, Department of Applied Research and Technological Development, Fondazione IRCCS Istituto Nazionale dei Tumori, Milan, Italy., Verderio P; Bioinformatics and Biostatistics Unit, Department of Applied Research and Technological Development, Fondazione IRCCS Istituto Nazionale dei Tumori, Milan, Italy., Tagliabue E; Molecular Targeting Unit, Department of Research, Fondazione IRCCS Istituto Nazionale dei Tumori, Milan, Italy., Di Cosimo S; Biomarkers Unit, Department of Applied Research and Technological Development, Fondazione IRCCS Istituto Nazionale dei Tumori, Milan, Italy., Iorio MV; Molecular Targeting Unit, Department of Research, Fondazione IRCCS Istituto Nazionale dei Tumori, Milan, Italy.
Publikováno v:
Cancer medicine [Cancer Med] 2022 Jan; Vol. 11 (2), pp. 332-339. Date of Electronic Publication: 2021 Dec 17.
Autor:
Di Cosimo S; Fondazione IRCCS Istituto Nazionale dei Tumori, Milano, Italy., Triulzi T; Fondazione IRCCS Istituto Nazionale dei Tumori, Milano, Italy., Pizzamiglio S; Fondazione IRCCS Istituto Nazionale dei Tumori, Milano, Italy., De Cecco L; Fondazione IRCCS Istituto Nazionale dei Tumori, Milano, Italy., de Azambuja E; Istitut Jules Bordet, Universitè Libre de Bruxelles, Belgium., Fumagalli D; Breast International Group (BIG)-aisbl, Bruxelles, Belgium., Putzai L; Yale Cancer Center, Yale School of Medicine, New Haven, USA., Harbeck N; Brustzentrum der Universität München (LMU), Munchen, Germany., Izquierdo M; Oncology Clinical Development, Oncology Business Unit, Novartis Pharma AG, Basel, Switzerland., Peña L; Vall D'Hebron Institute of Oncology, Barcelona, Spain., Daidone MG; Fondazione IRCCS Istituto Nazionale dei Tumori, Milano, Italy., Huober J; University of Ulm, Ulm, Germany., Gori S; IRCCS Sacro Cuore-Don Calabria Hospital, Negrar, Verona, Italy., Cinieri S; Antonio Perrino Hospital, Brindisi, Italy., Torri V; IRCCS - Istituto di Ricerche Farmacologiche 'Mario Negri' Milano, Italy., Baselga J; Vall D'Hebron Institute of Oncology, Barcelona, Spain., Piccart M; Istitut Jules Bordet, Universitè Libre de Bruxelles, Belgium., de Braud FG; Fondazione IRCCS Istituto Nazionale dei Tumori, Milano, Italy., Apolone G; Fondazione IRCCS Istituto Nazionale dei Tumori, Milano, Italy., Verderio P; Fondazione IRCCS Istituto Nazionale dei Tumori, Milano, Italy., Tagliabue E; Fondazione IRCCS Istituto Nazionale dei Tumori, Milano, Italy. Electronic address: elda.tagliabue@istitutotumori.mi.it.
Publikováno v:
European journal of cancer (Oxford, England : 1990) [Eur J Cancer] 2019 Sep; Vol. 118, pp. 1-9. Date of Electronic Publication: 2019 Jul 05.
Autor:
Giussani M; Molecular Targeting Unit, Fondazione IRCCS Istituto Nazionale dei Tumori, Milan, Italy., Landoni E; Medical Statistics, Biometry and Bioinformatics Unit, Fondazione IRCCS Istituto Nazionale dei Tumori, Milan, Italy., Merlino G; Biomarkers Unit, Fondazione IRCCS Istituto Nazionale dei Tumori, Milan, Italy., Turdo F; Molecular Targeting Unit, Fondazione IRCCS Istituto Nazionale dei Tumori, Milan, Italy., Veneroni S; Tissue Biobank, Fondazione IRCCS Istituto Nazionale dei Tumori, Milan, Italy., Paolini B; Anatomic Pathology A Unit, Fondazione IRCCS Istituto Nazionale dei Tumori, Milan, Italy., Cappelletti V; Biomarkers Unit, Fondazione IRCCS Istituto Nazionale dei Tumori, Milan, Italy., Miceli R; Medical Statistics, Biometry and Bioinformatics Unit, Fondazione IRCCS Istituto Nazionale dei Tumori, Milan, Italy., Orlandi R; Molecular Targeting Unit, Fondazione IRCCS Istituto Nazionale dei Tumori, Milan, Italy., Triulzi T; Molecular Targeting Unit, Fondazione IRCCS Istituto Nazionale dei Tumori, Milan, Italy., Tagliabue E; Molecular Targeting Unit, Fondazione IRCCS Istituto Nazionale dei Tumori, Milan, Italy.
Publikováno v:
Journal of cellular physiology [J Cell Physiol] 2018 Aug; Vol. 233 (8), pp. 6280-6290. Date of Electronic Publication: 2018 Mar 09.
Autor:
Triulzi T; Molecular Targeting Unit, Department of Experimental Oncology & Molecular Medicine, Fondazione IRCCS Istituto Nazionale dei Tumori, Milan, Italy., Bianchi GV; Department of Medical Oncology, Fondazione IRCCS Istituto Nazionale dei Tumori, Milan, Italy., Tagliabue E; Molecular Targeting Unit, Department of Experimental Oncology & Molecular Medicine, Fondazione IRCCS Istituto Nazionale dei Tumori, Milan, Italy.
Publikováno v:
Future oncology (London, England) [Future Oncol] 2016 Jun; Vol. 12 (11), pp. 1413-28. Date of Electronic Publication: 2016 Mar 23.
Autor:
Lucci MA; Department of Experimental Pathology, University of Pisa, Pisa, Italy., Orlandi R, Triulzi T, Tagliabue E, Balsari A, Villa-Moruzzi E
Publikováno v:
Cellular oncology : the official journal of the International Society for Cellular Oncology [Cell Oncol] 2010; Vol. 32 (5-6), pp. 361-72.
Akademický článek
Tento výsledek nelze pro nepřihlášené uživatele zobrazit.
K zobrazení výsledku je třeba se přihlásit.
K zobrazení výsledku je třeba se přihlásit.
Autor:
Anna Ianza, Tiziana Triulzi, Eva Ciruelos, Manuela Milani, Alfredo Molteni, Fabiola Giudici, Maria Rosaria Cappelletti, Silvia Paola Corona, Francesco Schettini, Carla Strina, Navid Sobhani, Guy Jerusalem, Sherine Loi, Stephen B. Fox, Daniele Generali, Ottavia Bernocchi, Maria Chiara Lazzari, Marianna Sirico
Publikováno v:
Breast Cancer Research and Treatment
Purpose mTOR inhibitor everolimus is used for hormone receptor-positive (HR+)/HER2-negative metastatic breast cancer (mBC). No reliable predictive biomarker of response is available. Following evidences from other solid tumors, we aimed to assess the
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::19e00b9b8ddae4330d6b3c438c58eedc
https://link.springer.com/article/10.1007/s10549-020-05856-3
https://link.springer.com/article/10.1007/s10549-020-05856-3